



11/22/02

1624

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/018,321	
	Filing Date	12/12/2001	
	First Named Inventor	SHIRAISHI, Mitsuru	
	Group Art Unit	1624	
	Examiner Name	tba	
Total Number of Pages in This Submission	6	Attorney Docket Number	2614 USOP

RECEIVED
NOV 25 2002

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard. Certificate of Express Mailing Cited Reference (1)
Remarks		The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account 500799.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	Mark Chao Ph.D., JD, Reg. No. 37,293
Signature	
Date	11/21/02

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as ^{EXPRESS} first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: 11/21/02			
Typed or printed name	Gail L. Winokur		
Signature		Date	11/21/02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Express Mail # EV 0826 5666545



#10
11/26/02
82

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/018,321 ✓
Filed: 12/12/2001 ✓
1st Inventor: SHIRAISHI, Mitsuru
For: Benzazepine Derivative, Production and
Use Thereof
Atty. Dkt. No. 2614 USOP ✓

Art Unit: 1624
Examiner: tba
Allowed:
Batch:
Paper No.:

RECEIVED
NOV 25 2002
TECH CENTER 1600/2900

Supplemental Information Disclosure Statement

Commissioner for Patents
Washington, D.C. 20231
Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, applicants request consideration of the reference listed on the attached form PTO-1449 under §1.97(c).

No Office Action or Notice of Allowance has been mailed in this case.

If necessary, Applicants herewith authorize the Commissioner to charge the Applicant's USPTO deposit account for the appropriate fee as set forth under 37 CFR §1.17(p) for submission of a supplemental Information Disclosure Statement.

Should the Examiner believe that a conference with applicants' attorney would advance prosecution of this application, the Examiner is respectfully invited to call applicants' attorney.


Respectfully submitted,

Dated: November 20, 2002

(847)383-3372
(847)383-3391

Mark Chao, Ph.D., Reg. No. 37,293
Elaine M. Ramesh, Ph.D., Reg. No. 43032
Attorney for Applicants
Customer No. 23115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	10/018,321	Art Unit:	1624
Filed:	12/12/2001	Examiner:	tba
1 st Inventor:	SHIRAISHI, Mitsuru	Allowed:	
For:	Benzazepine Derivative, Production and Use Thereof	Batch:	
Atty. Dkt. No.	2614 US0P	Paper No.:	

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10

USPS EXPRESS MAIL LABEL. No. EV 082656665 US

DATE IN: November 21, 2002

Itemized Papers/Items:


1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Form (1 page X 2)
3. Supplemental Information Disclosure Statement and PTO Form 1449 (2 pages), and cited reference (1)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

Commissioner for Patents
Washington, D.C. 20231.

on this date, 11/21/02

Dated: 11/21/02


Gail L. Winokur

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA

TECH CENTER 1600/2900

NOV 25 2002

RECEIVED